InMed Pharmaceuticals (INM) Expected to Release Quarterly Earnings on Wednesday

InMed Pharmaceuticals (NASDAQ:INM) is anticipated to announce its Q4 2026 results after the market closes on Wednesday, September 23rd. Analysts expect InMed Pharmaceuticals to post earnings of ($94.4436) per share and revenue of $2.0578 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Wednesday, September 9, 2026 at 7:00 AM ET.

InMed Pharmaceuticals (NASDAQ:INM) last issued its quarterly earnings data on Wednesday, September 9th. The company reported ($1.43) EPS for the quarter.

InMed Pharmaceuticals Price Performance

Shares of InMed Pharmaceuticals stock opened at $1.36 on Monday. InMed Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $2.50. The business has a 50 day moving average price of $1.46 and a 200-day moving average price of $1.22. The company has a market cap of $4.50 million, a PE ratio of -0.83 and a beta of 0.98.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Insider Activity at InMed Pharmaceuticals

In other news, major shareholder Adar1 Capital Management, Llc bought 54,256 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were purchased at an average price of $1.30 per share, with a total value of $70,532.80. Following the transaction, the insider directly owned 883,761 shares in the company, valued at $1,148,889.30. This represents a 6.54% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have purchased 97,652 shares of company stock worth $128,211. 0.85% of the stock is owned by company insiders.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of pharmaceutical products based on rare cannabinoids. The company combines cannabinoid science with drug-development expertise to investigate potential treatments for diseases with significant unmet medical needs.

Its research pipeline has included INM-901, an investigational rare-cannabinoid therapy being developed for Alzheimer’s disease, as well as earlier programs targeting conditions such as epidermolysis bullosa and glaucoma.